Trial Profile

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Lamivudine (Primary) ; Rilpivirine (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms COMBINE-2
Sponsors ViiV Healthcare

Most Recent Events

15 Jul 2024 According to a ViiV Healthcare media release, results form this study will be presented at the 25th International AIDS Conference in Munich, Germany (22 -26 July).
10 Nov 2023 Status changed from recruiting to completed.
08 Apr 2022 Planned End Date changed from 31 Dec 2021 to 31 Jan 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com